Lancet Oncology最新文献

{"title":"Correction to Lancet Oncol 2026; 27: e218-30.","authors":"","doi":"10.1016/S1470-2045(26)00165-8","DOIUrl":"https://doi.org/10.1016/S1470-2045(26)00165-8","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"27 5","pages":"e236"},"PeriodicalIF":35.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"War in the Middle East: collateral damage.","authors":"The Lancet Oncology","doi":"10.1016/S1470-2045(26)00187-7","DOIUrl":"https://doi.org/10.1016/S1470-2045(26)00187-7","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"27 5","pages":"527"},"PeriodicalIF":35.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Turning breast cancer into art with Cancer Research UK.","authors":"Daniel Mellor","doi":"10.1016/S1470-2045(26)00189-0","DOIUrl":"https://doi.org/10.1016/S1470-2045(26)00189-0","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"27 5","pages":"549-550"},"PeriodicalIF":35.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials.","authors":"Mohammed S Beshr, Ammar Fahaid, Rana H Shembesh, Antonios Valachis, Matteo Lambertini, Laura Cortesi, Alzahraa Faris Alesawy, Ahmed Abraheem, Mohamed Alsharedi, Mohamed E Ali, Ahmed Elkhanany, Hatem A Azim, Galina Velikova, Muhammed Elhadi","doi":"10.1016/S1470-2045(26)00053-7","DOIUrl":"https://doi.org/10.1016/S1470-2045(26)00053-7","url":null,"abstract":"<p><strong>Background: </strong>CDK4/6 inhibitors have shown clinical benefits in patients with hormone receptor-positive, HER2-negative advanced breast cancer. This meta-analysis aims to evaluate their effect on survival outcomes across clinically relevant subgroups.</p><p><strong>Methods: </strong>For this reconstructed individual patient-level meta-analysis, we searched PubMed, Web of Science, the Cochrane Library, and Scopus on June 2, 2025, for phase 3 trials that compared CDK4/6 inhibitors plus endocrine therapy with endocrine monotherapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer. Kaplan-Meier curves were reconstructed with the use of a time-to-event algorithm to retrieve survival data for individual patients. A series of pooled analyses for the reconstructed individual patient data were conducted with the use of a stratified Cox regression model. A pairwise random-effects meta-analysis was also conducted. Patients were stratified by endocrine sensitivity into endocrine-sensitive and endocrine-resistant, as well as by age, ethnicity, progesterone receptor status, menopausal status, Eastern Cooperative Oncology Group performance status, bone-only disease, and visceral metastasis. Primary outcomes analysed were progression-free survival and overall survival. The protocol is registered in PROSPERO (CRD420251073444).</p><p><strong>Findings: </strong>11 phase 3 trials, including 6035 patients and four agents-abemaciclib, ribociclib, palbociclib, and dalpiciclib-were included. CDK4/6 inhibitors plus endocrine therapy significantly improved progression-free survival in both endocrine-sensitive (HR 0·57, 95% CI 0·52-0·63; p<0·0001) and endocrine-resistant cancers (0·51, 0·45-0·57; p<0·0001). Overall survival was also improved with CDK4/6 inhibitors plus endocrine therapy in both subgroups: endocrine-sensitive (0·83; 0·74-0·92; p=0·0005) and endocrine-resistant (0·77; 0·67-0·89; p=0·0003). All individual agents, when combined with endocrine therapy showed progression-free survival benefits: abemaciclib (HR 0·53, 95% CI 0·46-0·61; p<0·0001), ribociclib (0·60, 0·52-0·68; p<0·0001), palbociclib (0·56, 0·49-0·65; p<0·0001), and dalpiciclib (0·49, 0·40-0·61; p<0·0001). However, only abemaciclib (0·79, 0·67-0·92; p=0·0031) and ribociclib (0·73, 0·64-0·84; p<0·0001) showed significant overall survival benefits; palbociclib did not reach statistical significance (0·89, 0·77-1·02; p=0·0920), and data for dalpiciclib remain immature. Other clinically relevant subgroups, stratified by age, ethnicity, progesterone receptor status, menopausal status, Eastern Cooperative Oncology Group performance status, bone-only disease, and visceral metastasis, showed progression-free survival and overall survival benefits in patients with endocrine-sensitive and endocrine-resistant tumours.</p><p><strong>Interpretation: </strong>CDK4/6 inhibitors plus endocrine therapy significantly improved survival in hormone receptor-positive, HER2-n","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"27 5","pages":"592-603"},"PeriodicalIF":35.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating total and diagnosed global cancer incidence and stage distribution from 1990 to 2050: a simulation-based analysis of 17 cancers.","authors":"Zachary J Ward, Fabio Ynoe Moraes, Andrew M Scott, Timothy R Rebbeck, Patrick J Loehrer, Hedvig Hricak","doi":"10.1016/S1470-2045(26)00060-4","DOIUrl":"https://doi.org/10.1016/S1470-2045(26)00060-4","url":null,"abstract":"<p><strong>Background: </strong>Cancer incidence is increasing globally, with the largest burden in low-income and middle-income countries. Workforce shortages and health system barriers contribute to substantial diagnostic delays and underdiagnosis, but estimates of undiagnosed cancer burden are lacking. The aim of this study was to estimate incidence (total and diagnosed) and stage at diagnosis in each country for 17 cancers from 1990 to 2050.</p><p><strong>Methods: </strong>We developed the Global Cancer Workforce microsimulation model to simulate 17 cancer types (oral, nasopharynx, oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, skin melanoma, breast, cervix uteri, ovary, prostate, bladder, and brain and CNS) in 200 countries and territories from 1990 to 2050, accounting for demographic trends and health system factors, including ten specific workforce personnel types relevant to cancer diagnosis. We calibrated the incidence module to empirical data on diagnosed cancer incidence and stage distribution at diagnosis. Using the calibrated model, we estimated both total (underlying) and diagnosed crude and age-standardised incidence rates (per 100 000 population) and numbers of cancer cases for each country and region from 1990 to 2050. We also estimated the proportion of cancers diagnosed at each stage (I-IV).</p><p><strong>Findings: </strong>Globally, among the 17 cancers included in the model, diagnosed cancer incidence was projected to increase from 13·58 million (95% uncertainty interval [UI] 12·17-14·51) cases in 2025 to 19·32 million (17·65-21·33) in 2050. Lung, breast, and prostate cancers were projected to remain the most commonly diagnosed cancers globally. The proportions of incident cancers that die undiagnosed showed large disparities by region, ranging from 0·9% (95% UI 0·6-1·3) in western Europe to 67·4% (60·1-74·2) in western Africa, with a global average of 31·5% (28·1-36·7). Globally, the proportion of cancers diagnosed at advanced stages (III-IV) was projected to decline slightly, from 45·7% (44·7-46·7) in 2025 to 44·7% (43·7-45·7) in 2050, with worse stage distributions in Africa and Asia compared with other regions.</p><p><strong>Interpretation: </strong>These findings highlight the substantial and growing burden of cancers, especially in low-income and middle-income countries, where many people who develop cancer die undiagnosed. Accounting for demographic and epidemiological trends as well as health system factors, our modelling framework enables evaluation of targeted interventions to strengthen the cancer workforce and improve diagnostic pathways across diverse geographical and socioeconomic settings.</p><p><strong>Funding: </strong>American Cancer Society and Breast Cancer Research Foundation.</p>","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"27 5","pages":"551-559"},"PeriodicalIF":35.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ionising radiation and cancer: a UN review of the recent epidemiological evidence.","authors":"Julie J Burtt, Amy Berrington de Gonzalez, Alina V Brenner, Robert D Daniels, Kyoji Furukawa, Klervi Leuraud, Mark P Little, David Pawel, Kristi Randhawa, David B Richardson","doi":"10.1016/S1470-2045(26)00115-4","DOIUrl":"https://doi.org/10.1016/S1470-2045(26)00115-4","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"27 5","pages":"534-537"},"PeriodicalIF":35.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards.","authors":"Gregor Laimer, Edward W Johnston, Christiaan G Overduin, Iwan Paolucci, Muneeb Ahmed, Ronald S Arellano, Marie Beermann, Lukas P Beyer, David J Breen, Mark C Burgmans, Marco Calandri, Ming-Chih Chern, Laura Crocetti, Ronald M van Dam, Alban Denys, Bjørn Edwin, Dimitrios Filippiadis, Yuman Fong, Nicos Fotiadis, Jacob Freedman, Åsmund A Fretland, Mariano Gimenez, Rodrigo G Garcia, Rosario F Grasso, Thomas K Helmberger, Pim Hendriks, Roberto Iezzi, Sjoerd Fm Jenniskens, Alexander Kupferthaler, Anja Lachenmayer, Fred T Lee, Jeong M Lee, Susan van der Lei, Christiaan van der Leij, Ping Liang, Charles C-W Lin, Lukas Luerken, Manuel Maglione, Andreas Mahnken, Justin P McWilliams, Marcos Menezes, Govindarajan Narayanan, Franco Orsi, Philippe L Pereira, Uei Pua, Robbert S Puijk, Hyunchul Rhim, William S Rilling, Simeon J S Ruiter, Anthony G Ryan, Peter Schullian, Paul B Shyn, Ajith K Siriwardena, Maarten L J Smits, Constantinos T Sofocleous, Luigi Solbiati, Vlasios Sotirchos, Stefan Stättner, Marco van Strijen, Trygve Syversveen, Pascale Tinguely, Lambros Tselikas, Jean-Nicolas Vauthey, Thomas J Vogl, Tze M Wah, Sarah B White, Philipp Wiggermann, Bradford J Wood, Jan van der Meulen, S Nahum Goldberg, Martijn R Meijerink, Bruno C Odisio, Reto Bale","doi":"10.1016/S1470-2045(26)00114-2","DOIUrl":"https://doi.org/10.1016/S1470-2045(26)00114-2","url":null,"abstract":"<p><p>Thermal ablation offers a safer, less invasive, and more cost-effective curative-intent treatment for selected patients with primary and metastatic liver tumours than surgery; when done with appropriate technique, ablation can deliver similar oncological outcomes. However, effectiveness in routine practice varies because structured training, planning, and procedural governance remain scarce. These international multidisciplinary, multi-society guidelines-formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology-define key domains contributing to procedural difficulty and practice variation in liver tumour thermal ablation. A Delphi consensus initiative held in Innsbruck, Austria, engaged 72 experts across three iterative rounds of scoring across 135 statements grouped into five domains: credentialing, indications, approach, procedural factors, and safety measures. Consensus was achieved for 94 (70%) of 135 statements. The least invasive route-typically percutaneous-should be prioritised, and margin adequacy was reaffirmed as the principal technical goal. Procedural difficulty was considered context-dependent, shaped by tumour factors, institutional infrastructure, and operator experience. Organ displacement techniques were endorsed to maintain safety and expand treatable indications. Complex ablations should be done by experienced operators (more than 100 previous cases), with programmes underpinned by structured training, multidisciplinary team participation, and routine audit. Future efforts should develop and validate practical tools such as difficulty scoring systems, standardised procedural reporting templates, and comprehensive training curricula to improve consistency, standardisation, and clinical outcomes globally.</p>","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"27 5","pages":"e259-e270"},"PeriodicalIF":35.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Academic clinical cancer trials to improve patient outcomes.","authors":"Denis Lacombe, Martin Stockler, Winette van der Graaf","doi":"10.1016/S1470-2045(26)00184-1","DOIUrl":"https://doi.org/10.1016/S1470-2045(26)00184-1","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"27 5","pages":"537-538"},"PeriodicalIF":35.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AKT-targeted triplet therapy in advanced breast cancer.","authors":"Lei Fan, Zhi-Ming Shao","doi":"10.1016/S1470-2045(26)00117-8","DOIUrl":"https://doi.org/10.1016/S1470-2045(26)00117-8","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"27 5","pages":"528-529"},"PeriodicalIF":35.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating the impact of scaling up workforce personnel on global cancer mortality from 2030 to 2050: a simulation-based analysis of 17 cancers and 18 personnel types.","authors":"Zachary J Ward, Fabio Ynoe Moraes, Andrew M Scott, Fernanda M Favorito, Wil Ngwa, Timothy R Rebbeck, Satish Gopal, Farouk Dako, Stephen Avery, Patrick J Loehrer, Hedvig Hricak","doi":"10.1016/S1470-2045(26)00062-8","DOIUrl":"https://doi.org/10.1016/S1470-2045(26)00062-8","url":null,"abstract":"<p><strong>Background: </strong>The global burden of cancer continues to rise, disproportionately affecting low-income and middle-income countries, where cancer workforce shortages are especially acute and contribute to poor outcomes. In this analysis, we estimate the effect on cancer mortality of scaling up specific workforce personnel types in order to provide global, regional, and country-specific guidance to inform cancer workforce policy.</p><p><strong>Methods: </strong>Using the Global Cancer Workforce microsimulation model, which accounts for demographic, epidemiological, and health system factors related to cancer incidence and survival, we modelled the projected effect of scaling up 18 specific workforce personnel types on total cancer mortality (diagnosed and undiagnosed) from 17 cancers (oral, nasopharynx, oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, skin melanoma, breast, cervix uteri, ovary, prostate, bladder, and brain and CNS) in 200 countries and territories from 2030 to 2050. Workforce density (per 100 000 population) of each workforce personnel type was modelled based on estimates from various sources (including WHO Global Health Workforce Statistics, the IMAGINE database, and previous Lancet Commissions). Expert opinion surveys, with responses from 86 experts in 16 countries, informed the involvement of workforce personnel in specific model events. We also modelled scale-up of workforce by cadre (ie, teams of personnel that work together in a particular specialty) and level of training (ie, years of education).</p><p><strong>Findings: </strong>Substantial disparities in cancer workforce were projected to persist in 2050, with especially large workforce shortages in Africa. Among single personnel types, scaling up surgeons was projected to yield the largest reduction in global cancer mortality (3·64% [95% uncertainty interval 2·68-4·66]), especially in Africa, Asia, and Oceania, but with considerable heterogeneity by country. Among workforce cadres, scaling up diagnostic and imaging personnel was projected to yield the greatest benefit (global cancer mortality reduction of 7·61% [5·23-9·88]), with some heterogeneity by country. Comprehensive scale-up of all workforce levels was projected to reduce cancer mortality by over 50% in 55 countries, most notably in Africa, central America, and southern Asia.</p><p><strong>Interpretation: </strong>Investments to strengthen the cancer workforce will be essential to reduce global cancer mortality and improve timely diagnosis and survival. Strategic scale-up of personnel, particularly in diagnostics, alongside innovative strategies such as digital health solutions and role delegation, could result in substantial improvements in cancer outcomes. Policy makers should prioritise data-driven workforce planning as a crucial component of comprehensive cancer control strategies.</p><p><strong>Funding: </strong>American Cancer Society and Breast Cancer Research Foundation.</p>","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"27 5","pages":"569-579"},"PeriodicalIF":35.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}